Dss Dose Titration
Dss Dose Titration - Related Videos
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
0 Views •
Cited by 607 •
2012
Experimental models of inflammatory bowel disease have allowed us to examine the complex innate and adaptive immune responses associated with pathogenesis. Using histological scoring, quantification of pro-inflammatory cytokines and myeloperoxidase activity, one can begin to assess these responses seen in inflammatory bowel disease.
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
0 Views •
Cited by 113 •
2010
Dextran sulfate sodium (DSS) administered in the drinking water is an established murine inflammatory injury model of acute colitis. This protocol outlines the method for DSS treatment and the preparation of tissues.
10:17
Introduction to Titration
0 Views •
2023
Source: Laboratory of Dr. Yee Nee Tan — Agency for Science, Technology, and Research Titration is a common technique used to quantitatively determine the unknown concentration of an identified analyte.1-4 It is also called volumetric analysis, as the measurement of volumes is critical in titration. There are many types of titrations based on the types of reactions they exploit. The most common types are acid-base titrations and redox titrations.5-11 In a typical titration process, a standard...
12:37
Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
0 Views •
Cited by 167 •
2012
We demonstrate a protocol in which administration of the genotoxic agent azoxymethane (AOM) followed by three cycles of the pro-inflammatory agent dextran sulfate sodium (DSS) rapidly and consistently generates colon tumors in mice with morphologic and molecular similarities to those seen in human colitis-associated cancer.
06:58
n-Butyllithium Titration
0 Views •
2023
Source: Vy M. Dong and Diane Le, Department of Chemistry, University of California, Irvine, CA This experiment will demonstrate a simple technique to titrate and obtain an accurate concentration of the organolithium reagent, n-butyllithium (n-BuLi). Organolithium reagents are extremely air- and moisture-sensitive and proper care must be taken to maintain the quality of the reagent so that it may be used successfully in a reaction. The n-BuLi titration experiments should be performed regularly...
FAQs
Researchers compare defined DSS concentrations with the resulting severity of intestinal injury. As dose-related changes appear in body weight, stool characteristics, bleeding, colon length, and tissue pathology, the pattern indicates how strongly the model responds across conditions. This relationship helps identify an experimental range that produces measurable, graded disease rather than an uncontrolled or poorly differentiated outcome.
No single measurement captures every aspect of intestinal injury. Body weight and stool findings describe clinical severity, bleeding provides an additional disease indicator, colon length reflects structural change, and tissue pathology shows alterations in the intestine. Reviewing these measures together strengthens interpretation of the dose response and supports more consistent comparisons among experimental groups.
Different dose conditions can produce disease patterns suitable for either acute or chronic colitis research. Comparing clinical findings, colon length, and tissue pathology across the tested range helps researchers determine which conditions reproduce the intended level and form of injury. Selecting the appropriate model is important when studying inflammation-driven colorectal cancer or evaluating interventions over different disease contexts.
An appropriate dose must create a sufficiently clear and reproducible intestinal response while avoiding excessive morbidity. Researchers therefore weigh the observed disease severity against the study’s purpose, using body weight, stool characteristics, bleeding, colon length, and tissue pathology as evidence. This balance improves experimental consistency and prevents an injury level that could obscure disease mechanisms or treatment effects.
The workflow begins by administering defined DSS concentrations, followed by assessment of disease-related changes using clinical observations and tissue-based measures. Researchers then compare outcomes across concentrations to map the dose response and select conditions that match the desired acute or chronic colitis model. The selected range can subsequently support studies of mechanisms, prevention strategies, or therapeutics.
It is especially useful when inflammation-driven colorectal cancer studies require a reproducible intestinal injury background. By identifying conditions that generate controlled colitis, researchers can examine disease mechanisms and test prevention strategies or therapeutics under comparable levels of inflammation. The titration process also helps limit excessive morbidity, which supports clearer interpretation of experimental outcomes and improves consistency between studies.